Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Tumor immunity: a novel dimension for PROTACs to conquer cancer?

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: PROTACs drive neoantigen presentation and T cell activation.

References

  1. Pearlman AH, Hwang MS, Konig MF, Hsiue EH, Douglass J, DiNapoli SR, et al. Targeting public neoantigens for cancer immunotherapy. Nat Cancer. 2021;2:487–97.

    CAS  Article  Google Scholar 

  2. Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers. 2021;13:134.

    CAS  Article  Google Scholar 

  3. Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021;184:4032–47.

    CAS  Article  Google Scholar 

  4. Fidanza M, Gupta P, Sayana A, Shanker V, Pahlke S-M, Vu B, et al. Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma. Sci Transl Med. 2021;13:eaax4100.

  5. Douglass J, Hsiue EH-C, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, et al. Bispecific antibodies targeting mutant RAS neoantigens. Sci Immunol. 2021;6:eabd5515.

    CAS  Article  Google Scholar 

  6. Bond MJ, Chu L, Nalawansha DA, Li K, Crews CM. Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs. ACS Cent Sci. 2020;6:1367–75.

    CAS  Article  Google Scholar 

  7. Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020;181:102–14.

    CAS  Article  Google Scholar 

  8. Moser SC, Voerman JS, Buckley DL, Winter GE, Schliehe C. Acute pharmacologic degradation of a stable antigen enhances its direct presentation on MHC class I molecules. Front Immunol. 2018;8:1920.

    Article  Google Scholar 

  9. Jensen SM, Potts GK, Ready DB, Patterson MJ. Specific MHC-I peptides are induced using PROTACs. Front Immunol. 2018;9:2697.

    Article  Google Scholar 

  10. Massafra V, Tundo S, Dietzig A, Ducret A, Jost C, Klein C, et al. Proteolysis-targeting chimeras enhance T cell bispecific antibody-driven T cell activation and effector function through increased MHC class I antigen presentation in cancer cells. J Immunol. 2021;207:493–504.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 31971371 to ZZ), and Zhejiang University K.P.Chao’s High Technology Development Foundation. The figures were created with BioRender.com.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Wen-bin Zhao, Zhan Zhou or Ji Cao.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, Xk., Zhao, Wb., Zhou, Z. et al. Tumor immunity: a novel dimension for PROTACs to conquer cancer?. Acta Pharmacol Sin 43, 2171–2172 (2022). https://doi.org/10.1038/s41401-021-00829-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41401-021-00829-8

Search

Quick links